NVAX:NASDAQ
Novavax Inc
12,64 $
arrow_downward
-1,40%(-0,18) 1D
12,39 $
arrow_downward
-2,01% (-0,25)todayPre-market
Closed: 14 հոկ, 16:00:00 GMT-4 · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for NVAX...
Open
12,69 $
High
13,34 $
Low
12,57 $
Mkt. cap
2,08 մլրդ
Avg. vol.
7,47 մլն
Volume
41,14 հզր
52-wk high
13,38 $
52-wk low
6,20 $
EPS
-1,52 $
Beta
2,44
Shares outstanding
164,95 մլն
No. of employees
749
Open
12,69 $
High
13,34 $
Low
12,57 $
Mkt. cap
2,08 մլրդ
Avg. vol.
7,47 մլն
Volume
41,14 հզր
52-wk high
13,38 $
52-wk low
6,20 $
EPS
-1,52 $
Beta
2,44
Shares outstanding
164,95 մլն
No. of employees
749
News stories
From web sources and news partners
News Corp
·
1 օր առաջ
Novavax Inc. stock outperforms competitors on strong trading day
Yahoo Finance
·
1 օր առաջ
Novavax (NVAX) Increases Despite Market Slip: Here's What You Need to Know
24/7 Wall St.
·
5 օր առաջ
Novavax Soars 16%, Moderna Surges 11%, Merck Climbs 3% as Biotech Rallies
Profile
Novavax, Inc., based in Gaithersburg, Maryland, develops vaccines to counter infectious diseases. The company developed the Novavax COVID-19 vaccine, now commercialized by Sanofi. The company also develops vaccines for influenza, respiratory syncytial virus, avian flu, shingles, Clostridioides difficile, and malaria.
Novavax develops proprietary immune-stimulating saponin-based immunologic adjuvants at a wholly owned Swedish subsidiary, Novavax AB. One of these, Matrix-M, is used in the Novavax COVID-19 vaccine. Wikipedia
About Novavax Inc
CEOJohn C. Jacobs
Employees749
Founded1987
HeadquartersGaithersburg, Մերիլենդ, Միացյալ Նահանգներ
Sector-
Websitenovavax.com